flortaucipir F 18 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5396 | 1522051-90-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Flortaucipir F 18 is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD). It binds to aggregated tau protein. In the brains of patients with AD, tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD. In vitro, flortaucipir F 18 binds to paired helical filament (PHF) tau purified from brain homogenates of donors with AD. The dissociation constant (Kd) of flortaucipir F 18 binding to PHFs is 0.57 nM. In vivo, flortaucipir F 18 is differentially retained in neocortical areas that contain aggregated tau. In vitro, tritiated flortaucipir has been reported to bind with low nanomolar affinity to monoamine oxidase-A and monoamine oxidase-B, which could contribute to off target binding
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 28, 2020 | FDA | AVID RADIOPHARMS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V09AX07 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS CENTRAL NERVOUS SYSTEM Other central nervous system diagnostic radiopharmaceuticals |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Positron emission tomography | indication | 82918005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 30ML (8.1-51mCi/ML) | TAUVID | AVID RADIOPHARMS INC | N212123 | May 28, 2020 | RX | SOLUTION | INTRAVENOUS | May 28, 2025 | NEW CHEMICAL ENTITY |
| 50ML (8.1-51mCi/ML) | TAUVID | AVID RADIOPHARMS INC | N212123 | May 28, 2020 | RX | SOLUTION | INTRAVENOUS | May 28, 2025 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Microtubule-associated protein tau | Structural | BINDING AGENT | Kd | 9.24 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D11210 | KEGG_DRUG |
| T1JP1KYU9O | UNII |
| 1415379-56-4 | SECONDARY_CAS_RN |
| C4742689 | UMLSCUI |
| CHEMBL3545253 | ChEMBL_ID |
| 70957463 | PUBCHEM_CID |
| DB14914 | DRUGBANK_ID |
| CHEMBL3546271 | ChEMBL_ID |
| 9100 | IUPHAR_LIGAND_ID |
| DB15033 | DRUGBANK_ID |
| 018380 | NDDF |
| 878816002 | SNOMEDCT_US |
| 879808000 | SNOMEDCT_US |
| 4041601 | VANDF |
| 2372689 | RXNORM |
| 41402 | MMSL |
| d10033 | MMSL |
| 10203 | INN_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TAUVID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-1210 | INJECTION, SOLUTION | 51 mCi | INTRAVENOUS | NDA | 25 sections |
| TAUVID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-1210 | INJECTION, SOLUTION | 51 mCi | INTRAVENOUS | NDA | 25 sections |
| TAUVID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-1220 | INJECTION, SOLUTION | 100 mCi | INTRAVENOUS | NDA | 25 sections |